These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 22664119)

  • 1. The effect of combined therapy with deferoxamine and deferiprone on serum ferritin level of beta-thalassemic patients.
    Mirbehbahani N; Jahazi A; Rahim Abad HH
    Hematology; 2012 May; 17(3):183-6. PubMed ID: 22664119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
    Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
    Taher A; Sheikh-Taha M; Koussa S; Inati A; Neeman R; Mourad F
    Eur J Haematol; 2001 Jul; 67(1):30-4. PubMed ID: 11553264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone.
    Alymara V; Bourantas D; Chaidos A; Bouranta P; Gouva M; Vassou A; Tzouvara E; Bourantas KL
    Hematol J; 2004; 5(6):475-9. PubMed ID: 15570288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience.
    Abdelrazik N
    Hematology; 2007 Dec; 12(6):577-85. PubMed ID: 17852442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Pibiri M; Nair SV; Walker JM; Pennell DJ
    J Cardiovasc Magn Reson; 2008 Feb; 10(1):12. PubMed ID: 18298856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coenzyme Q10 levels in β-thalassemia and its association with ferritin levels and chelation therapy.
    Karakukcu C; Karakukcu M; Unal E; Patiroglu T; Ozdemir MA; Torun YA; Tang PH
    Hemoglobin; 2012; 36(3):219-29. PubMed ID: 22483337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and adverse effects of oral iron chelator deferiprone (l1, 1,2- dimethyl-3-hydroxypyrid-4-one) in patients with beta thalassaemia major in Pakistan.
    Ayyub M; Ali W; Anwar M; Waqar A; Khan MN; Ijaz A; Hussain T; Hussain S
    J Ayub Med Coll Abbottabad; 2005; 17(4):12-5. PubMed ID: 16599026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined oral and parenteral iron chelation in beta thalassaemia major.
    Balveer K; Pyar K; Wonke B
    Med J Malaysia; 2000 Dec; 55(4):493-7. PubMed ID: 11221163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
    Ha SY; Chik KW; Ling SC; Lee AC; Luk CW; Lam CW; Ng IO; Chan GC
    Hemoglobin; 2006; 30(2):263-74. PubMed ID: 16798652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
    El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
    Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.
    Kolnagou A; Kontoghiorghes GJ
    Hemoglobin; 2006; 30(2):239-49. PubMed ID: 16798649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of deferiprone and deferrioxamine for the treatment of transfusional iron overload in children with beta thalassemia major.
    Waheed N; Ali S; Butt MA
    J Ayub Med Coll Abbottabad; 2014; 26(3):297-300. PubMed ID: 25671931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination.
    Kolnagou A; Kontoghiorghe CN; Kontoghiorghes GJ
    Drug Res (Stuttg); 2017 Jul; 67(7):404-411. PubMed ID: 28320041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deferiprone or deferoxamine vs. combination therapy in patients with beta-thalassemia major: a case study in Taiwan.
    Peng CT; Wu KH; Wu SF; Liang DC; Yang CP; Jang RC; Wang LY; Hsiao CC
    Hemoglobin; 2006; 30(1):125-30. PubMed ID: 16540425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
    Tsironi M; Assimakopoulos G; Polonofi K; Rigaki K; Aessopos A
    Hemoglobin; 2008; 32(1-2):29-34. PubMed ID: 18274980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*.
    Ha SY; Mok AS; Chu WC; Raskalkar DD; Cheuk DK; Chiang AK; Ho MH; Chan GC
    Hemoglobin; 2009; 33(5):323-31. PubMed ID: 19814678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis.
    Pennell DJ; Berdoukas V; Karagiorga M; Ladis V; Piga A; Aessopos A; Gotsis ED; Tanner MA; Smith GC; Westwood MA; Wonke B; Galanello R
    Blood; 2006 May; 107(9):3738-44. PubMed ID: 16352815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, compliance and toxicity factors are affecting the rate of normalization of body iron stores in thalassemia patients using the deferiprone and deferoxamine combination therapy.
    Kolnagou A; Kleanthous M; Kontoghiorghes GJ
    Hemoglobin; 2011; 35(3):186-98. PubMed ID: 21599431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.